核糖核苷酸还原酶和非小细胞肺癌

Ribonucleotide Reductase and Non-small Cell Lung Cancer Nan-Yung HSU, Hue LEE, Ya-Wen CHENG, Yun YEN Division of Thoracic Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, China; International Cancer Institute, Taipei Medical University Hospital, Taipei, China; School of Medicine, Taipei Medical University, Taipei, China; College of Medical Science and Technology, Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, China Corresponding author: Yun YEN, E-mail: yyen@tmu.edu.tw DOI: 10.3779/j.issn.1009-3419.2012.11.02

[1]  M. Grever,et al.  A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors , 2013, Investigational New Drugs.

[2]  J. Stubbe,et al.  Mechanistic Studies of Semicarbazone Triapine Targeting Human Ribonucleotide Reductase in Vitro and in Mammalian Cells , 2012, The Journal of Biological Chemistry.

[3]  G. Bepler,et al.  Preliminary indication of survival benefit from ERCC1 and RRM1‐tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis , 2012, Cancer.

[4]  Y. Yen,et al.  Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. , 2011, Anticancer research.

[5]  C. Dumontet,et al.  The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. , 2011, The Lancet. Oncology.

[6]  G. Pond,et al.  A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Hiroshi Terada,et al.  Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. , 2009, Colloids and surfaces. B, Biointerfaces.

[8]  A. Mizuno,et al.  Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. , 2009, Oral oncology.

[9]  Y. Yen,et al.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study , 2009, Cancer Chemotherapy and Pharmacology.

[10]  M. Grever,et al.  Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[11]  F. Torti,et al.  A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma , 2008, Cancer Chemotherapy and Pharmacology.

[12]  M. Spitz,et al.  Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. , 2007, Cancer research.

[13]  Ulla Vogel,et al.  The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. , 2007, Lung cancer.

[14]  Lijun Xue,et al.  Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells , 2006, Clinical Cancer Research.

[15]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[16]  Y. Yen,et al.  Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues. , 2006, Hybridoma.

[17]  Dong Sun Kim,et al.  Polymorphisms in the caspase-8 gene and the risk of lung cancer. , 2006, Cancer genetics and cytogenetics.

[18]  Y. Lee,et al.  GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. , 2006, International journal of oncology.

[19]  C. Der,et al.  Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells , 2004, Journal of Biological Chemistry.

[20]  Lijun Xue,et al.  Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. , 2004, Biochemical pharmacology.

[21]  A. Chabes,et al.  S Phase-specific Transcription of the Mouse Ribonucleotide Reductase R2 Gene Requires Both a Proximal Repressive E2F-binding Site and an Upstream Promoter Activating Region* , 2004, Journal of Biological Chemistry.

[22]  Yate-Ching Yuan,et al.  In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase , 2004, Cancer Research.

[23]  Lijun Xue,et al.  The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. , 2003, Cancer research.

[24]  J. Minna,et al.  Lung cancer • 9: Molecular biology of lung cancer: clinical implications , 2003, Thorax.

[25]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[26]  Yusuke Nakamura,et al.  Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells* , 2001, The Journal of Biological Chemistry.

[27]  R. M. Orr.  GTI-2040. Lorus Therapeutics. , 2001, Current opinion in investigational drugs.

[28]  X. Tu,et al.  GTI-2501. Lorus Therapeutics. , 2001, Current opinion in investigational drugs.

[29]  K. Vousden,et al.  A ribonucleotide reductase gene is a transcriptional target of p53 and p73 , 2000, Oncogene.

[30]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[31]  J. Wright,et al.  The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. , 1998, Cancer research.

[32]  Yun Yen,et al.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential , 1998, Clinical & Experimental Metastasis.

[33]  R. Currie.  NF-Y Is Associated with the Histone Acetyltransferases GCN5 and P/CAF* , 1998, The Journal of Biological Chemistry.

[34]  J. Wright,et al.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. K. Chan,et al.  Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. , 1990, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[36]  G. Mann,et al.  Tyrosyl free radical formation in the small subunit of mouse ribonucleotide reductase. , 1990, The Journal of biological chemistry.

[37]  Y. Engström,et al.  Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. , 1985, The Journal of biological chemistry.

[38]  L. Tanoue,et al.  Molecular Origins of Cancer. Lung Cancer , 2010 .

[39]  Y. Yen,et al.  p 53 R 2 expression as a prognostic biomarker in early stage non-small cell lung cancer , 2010 .

[40]  S. Natsugoe,et al.  Expression of p 53 R 2 Is Related to Prognosis in Patients with Esophageal Squamous Cell Carcinoma , 2006 .

[41]  Lijun Xue,et al.  Wild-Type p 53 Regulates Human Ribonucleotide Reductase by Protein-Protein Interaction with p 53 R 2 as well as hRRM 2 Subunits 1 , 2003 .

[42]  B. Cooperman,et al.  A comprehensive model for the allosteric regulation of Class Ia ribonucleotide reductases. , 2003, Advances in enzyme regulation.

[43]  Yusuke Nakamura,et al.  p 53 R 2-dependent Pathway for DNA Synthesis in a p 53-regulated Cell Cycle Checkpoint 1 , 2001 .

[44]  P. Reichard,et al.  Interactions between deoxyribonucleotide and DNA synthesis. , 1988, Annual review of biochemistry.